Clearside Biomedical up after eye drug trial updates

Clearside Biomedical,

18/04/2023 16:17

** Shares of drug developer Clearside Biomedical Inc
 CLSD.O  up 2.8% at $1.12 
    ** Co announced plans to open its eye-disorder drug trial
for enrollment this quarter
    ** The late-stage trial to test the drug in patients with
wet age-related macular degeneration, a chronic eye disorder
causing blurred vision or a blind spot in one's visual field
    ** Expects top-line results in Q3 2024
    ** Stock down 41% in last 12 months

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))